Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bipartisan Bills To Promote Drug Competition A Step Closer To Completion

The Two Bills Have Passed The Senate Judiciary Committee By Voice Vote

Executive Summary

The Preserving Access to Affordable Generics and Biosimilars Act and the Stop STALLING Act are both a step closer to  becoming law after passing voice votes in the Senate Judiciary Committee.

You may also be interested in...



Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap

Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.

New Insulin Manufacturer For Civica

Ypsomed AG will manufacture insulin dosing injector pens for non-profit Civica. Civica has also paired up with AmerisourceBergen for generics supply chain support across the US.

Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law

With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel